Drug recall · December 28, 2016
BuPROPion Hydrochloride Extended-Release Tablets recall
Why: Failed Dissolution Specifications; 6 month time point
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
BuPROPion Hydrochloride Extended-Release Tablets (XL), 300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534
- Lots / codes
a) MS1667 exp 01/2018; M601708, exp 03/2018; b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018
- Quantity
- 16,356 bottles
- Company
- Zydus Pharmaceuticals USA Inc, Pennington, NJ
- Distribution
- Nationwide
- Initiated
- November 2, 2016 · Voluntary: Firm initiated
- Classified
- December 20, 2016
- Reported
- December 28, 2016
- Ended
- July 23, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupropion
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.